View Older Stories View More Recent Stories

Aug 16, 2018 07:00AM Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Aug 16, 2018 07:00AM Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Aug 13, 2018 07:05AM Regeneron (REGN) Announces Regulatory Update on EYLEA (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Aug 13, 2018 07:00AM Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
Aug 6, 2018 06:31AM Regeneron (REGN), bluebird bio (BLUE) Announce Pact to Discover, Develop and Commercialize New Cell Therapies for Cancer
Aug 6, 2018 06:30AM bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Aug 6, 2018 06:30AM Regeneron and bluebird bio Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer
Aug 3, 2018 07:30AM Regeneron Announces the 2018 Winners of the Regeneron Prize for Creative Innovation
Aug 2, 2018 06:30AM Regeneron Reports Second Quarter 2018 Financial and Operating Results
Jul 9, 2018 09:30AM Regeneron to Report Second Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on August 2, 2018
Jun 6, 2018 07:00AM Regeneron (REGN), Zoetis (ZTS) Announce Collaboration to Research Antibody Therapies for Use in Animal Health
Jun 6, 2018 07:00AM Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health
Jun 4, 2018 02:18PM Sanofi (SNY), Regeneron (REGN) Announce NEJM Published Pivotal Cemiplimab Trials showing Positive Results in Advanced CSCC
Jun 4, 2018 02:16PM Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
May 31, 2018 04:05PM Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak
May 21, 2018 02:16PM Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 21, 2018 02:15PM Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 21, 2018 02:15PM Regeneron (REGN) Says NEJM Published Two Positive Phase 3 Trials Showing DUPIXENT Improved Moderate-to-Severe Asthma
May 21, 2018 02:15PM New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 21, 2018 02:14PM New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma
May 18, 2018 09:30AM Regeneron Announces Upcoming Investor Conference Presentation
May 16, 2018 05:04PM Regeneron (REGN), Sanofi (SNY) Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
May 16, 2018 05:00PM Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
May 16, 2018 08:00AM Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 05:50AM Sanofi (SNY) & Regeneron (REGN) Report Dupixent (dupilumab) Showed Positive Phase 3 Results in Adolescents with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis
May 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 01:01AM Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
May 16, 2018 01:01AM Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
May 16, 2018 01:00AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 3, 2018 06:30AM Regeneron Reports First Quarter 2018 Financial and Operating Results
May 1, 2018 07:06AM Sanofi (SNY) and Regeneron (REGN) to Lower Net Price of Praluent; Praluent will become Exclusive PCSK9 inhibitor Therapy on Express Scripts (ESRX) National Formulary
May 1, 2018 07:00AM Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients
May 1, 2018 06:59AM Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
Apr 30, 2018 05:48AM Regeneron (REGN) Reports Acceptance for FDA Priority Review of BLA for Cemiplimab
Apr 30, 2018 01:01AM Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 30, 2018 01:00AM FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 30, 2018 01:00AM FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 23, 2018 09:30AM Regeneron Announces Upcoming Investor Conference Presentations
Apr 9, 2018 09:30AM Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018
Apr 3, 2018 05:48AM Regeneron (REGN) & Sanofi (SNY) Report EMA to Review Cemiplimab as Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 3, 2018 05:44AM Regeneron (REGN) & Sanofi (SNY) Report EMA to Review DUPIXENT (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma
Apr 3, 2018 01:01AM EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma
Apr 3, 2018 01:00AM Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
Apr 3, 2018 01:00AM Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
Apr 3, 2018 01:00AM EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
View More Recent Stories View Older Stories